HSC aging comes with expansion of myeloid-biased clones, accumulation of mutations and loss of regenerative potential. It was already known that transplanting old HSCs into a young microenvironment does not fully restore their function, which points to cell-intrinsic aging mechanisms. Neighboring papers in the archive deal with cellular senescence, epigenetic landscapes and atomic-scale control of light, but none of them touch HSC reprogramming in vivo. This work fills that gap by showing that brief partial reprogramming can durably change the aging trajectory of HSCs.
The team used transgenic mice with doxycycline-inducible expression of the four Yamanaka factors (Oct4, Sox2, Klf4, c-Myc). At 2-3 months of age, the mice received doxycycline in their drinking water for 16 days, after which the animals were left untreated until 20-24 months of age. Effects were assessed by flow cytometry, competitive bone marrow transplantation, RNA sequencing (bulk and single-cell), ATAC-seq for chromatin accessibility and CUT&Tag for the heterochromatin mark H3K9me3. The contribution of mobile elements was additionally tested with the reverse transcriptase inhibitor lamivudine, and the role of AP-1 with the inhibitor T-5224.
A single induction of OSKM in youth prevented the age-related increase in HSC numbers, myeloid skewing and accumulation of DNA damage (γH2AX foci). In old mice that had received doxycycline, blood and bone marrow parameters recovered to levels close to those of young animals. Transcriptome analysis showed that the expression profile of old treated HSCs was closer to young cells than to untreated old ones. Epigenetically, reprogramming prevented the loss of H3K9me3 at mobile elements and chromatin opening at AP-1 binding sites. Inhibiting reverse transcriptase with lamivudine improved the function of old HSCs, confirming the contribution of mobile elements. The AP-1 inhibitor T-5224 prevented inflammation-induced loss of clonogenicity but had no effect on already reprogrammed cells.
The work shows that HSC aging is largely epigenetically reversible: a short exposure to Yamanaka factors creates a durable state resistant to age-related stress. Unlike neighboring papers that describe age-related changes, this study is the first to demonstrate that a single intervention in young age produces a long-term protective effect. That shifts the focus from correcting already aged cells to preventing aging through early epigenetic reprogramming.
It may be possible to adapt similar approaches for humans, for instance with small molecules that mimic the action of OSKM, or with temporary expression of the factors in culture before transplantation. It will also be promising to study exactly how the epigenetic memory is formed and whether it can be erased or rewritten. Another key question is whether this mechanism works in other stem cell systems and under different types of stress.
The results could shape strategies for rejuvenating the blood system, preventing age-related blood disorders and improving bone marrow transplant outcomes. Understanding the role of AP-1 and mobile elements opens new targets for drug intervention.
It is necessary to find out which epigenetic modifications are responsible for the long-term memory and to determine the minimal set of factors sufficient to protect HSCs. The next step will be to test the safety and efficacy of the approach in models closer to humans.
The work speaks directly to the unresolved problem of stem cell aging reversibility: until now it was unclear whether age-related changes could be prevented, not just slowed down. It also links epigenetic instability to mobile element activation and inflammatory stress, which remains poorly studied in hematology.
A single 16-day course of doxycycline in youth protected mice from the age-related decline in blood formation for almost their entire lives, even though the Yamanaka factors themselves stopped being expressed after just a month.
Not published on arXiv. Here are its page, the PDF and the formalization: you can check it yourself, not only read our account.